Research programme: cyclin-dependent kinase inhibitors - Virostatics
Latest Information Update: 27 Mar 2023
At a glance
- Originator Virostatics
- Class Antineoplastics; Antiretrovirals; Antivirals; Small molecules
- Mechanism of Action Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; COVID 2019 infections; HIV infections
- No development reported Epstein-Barr virus infections; Hepatitis B; Varicella zoster virus infections
- Discontinued Ebola virus infections; Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections; Human papillomavirus infections
Most Recent Events
- 27 Mar 2023 Preclinical trials in COVID-2019 infections in Italy (PO) before March 2023(Virostatics pipeline, March 2023)
- 27 Mar 2023 Virostatics plans a clinical trials for COVID-2019 infections (Virostatics pipeline, March 2023)
- 02 Dec 2022 Preclinical development for Cancer is ongoing in Italy (Virostatics pipeline, December 2022)